1
|
Carrillo-Santisteve P, Tavoschi L, Severi E, Bonfigli S, Edelstein M, Byström E, Lopalco P. Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review. THE LANCET. INFECTIOUS DISEASES 2017. [PMID: 28645862 DOI: 10.1016/s1473-3099(17)30392-4] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Most of the European Union (EU) and European Economic Area (EEA) is considered a region of very low hepatitis A virus (HAV) endemicity; however, geographical differences exist. We did a systematic review with the aim of describing seroprevalence and susceptibility in the general population or special groups in the EU and EEA. We searched databases and public health national institutes websites for HAV seroprevalence records published between Jan 1, 1975, and June 30, 2014, with no language restrictions. An updated search was done on Aug 10, 2016. We defined seroprevalence profiles (very low, low, and intermediate) as the proportion of the population with age-specific anti-HAV antibodies at age 15 and 30 years, and susceptibility profiles (low, moderate, high, and very high) as the proportion of susceptible individuals at age 30 and 50 years. We included 228 studies from 28 of 31 EU and EEA countries. For the period 2000-14, 24 countries had a very low seroprevalence profile, compared with five in 1975-89. The susceptibility among adults ranged between low and very high and had a geographical gradient, with three countries in the low susceptibility category. Since 1975, EU and EEA countries have shown decreasing seropositivity; however, considerable regional variability exists. The main limitations of this study are that the studies retrieved for analysis might not be representative of all EU and EEA publications about HAV and might have poor national representativeness. A large proportion of EU and EEA residents are now susceptible to HAV infection. Our Review supports the need to reconsider specific prevention and control measures, to further decrease HAV circulation while providing protection against the infection in the EU and EEA, and could be used to inform susceptible travellers visiting EU and EEA countries with different HAV endemicity levels.
Collapse
Affiliation(s)
| | - Lara Tavoschi
- European Centre for Disease Prevention and Control, Solna, Sweden
| | - Ettore Severi
- European Centre for Disease Prevention and Control, Solna, Sweden; Karolinska Institutet, Stockholm, Sweden
| | - Sandro Bonfigli
- European Centre for Disease Prevention and Control, Solna, Sweden; Ministry of Health, Rome, Italy
| | - Michael Edelstein
- European Centre for Disease Prevention and Control, Solna, Sweden; Public Health Agency of Sweden, Stockholm, Sweden
| | - Emma Byström
- Public Health Agency of Sweden, Stockholm, Sweden
| | - Pierluigi Lopalco
- European Centre for Disease Prevention and Control, Solna, Sweden; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
| | | |
Collapse
|
2
|
Betsas G, Karamba S, Daniilidis A, Rousso D, Karagiannis T, Sofianoy D, Karagiannis V. Prevalence of Hepatitis B Virus (HBV) Inflammation in Pregnant Women in Northern Greece. EUR J INFLAMM 2016. [DOI: 10.1177/1721727x0600400207] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
One of the most challenging problems in obstetrics is the issue of prenatal infections. This problem is particularly acute in some areas. Northern Greece is such an area, due to the immigration of about 250,000 people in the last 5 to 10 years. We estimated the prevalence of hepatitis B virus (HBV) antigen (HbsAg) positive women who presented for their first prenatal visit during the calendar year 2004. The rate was 1% in native Greek women (n=239) and 6% in immigrant women (n=305), (p<0.0059).
Collapse
Affiliation(s)
| | - S. Karamba
- Laboratory of Microbiology, Hippokration General Hospital, Thessaloniki, Greece
| | | | | | | | - D. Sofianoy
- Laboratory of Microbiology, Hippokration General Hospital, Thessaloniki, Greece
| | | |
Collapse
|
3
|
Ozdemir O, Arda K, Soylu M, Alyan O, Demir AD, Kütük E. Seroprevalence of hepatitis B and C in subjects admitted to a cardiology clinics in Turkey. Eur J Epidemiol 2016; 18:255-8. [PMID: 12800951 DOI: 10.1023/a:1023338423566] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
A seroepidemiological study was conducted to assess the seroprevalence of hepatitis B surface antigen (HBs Ag) and antibodies to hepatitis C virus (Anti-HCV) in 14,196 patients hospitalized in our cardiology clinics. Threehundred and fifty five (355) patients (2.43%) were found to be positive for HBs Ag, a hundred and sixty six (166) patients (1.09%) were positive for Anti-HCV and ten patients (0.07%) were positive for both. The presence of HBs Ag and Anti-HCV was similar in patients living in rural and urban areas. The presence of risk factors was greater in the patients with Anti-HCV. The prevalences of HBs Ag and Anti-HCV were found to be comparable with those reported in other mediterranean countries in Europe.
Collapse
Affiliation(s)
- O Ozdemir
- Cardiology Clinics, Türkiye Yüksek Ihtisas Hospital, Sihhiye Ankara, Turkey
| | | | | | | | | | | |
Collapse
|
4
|
|
5
|
Sypsa V, Hadjipaschali E, Hatzakis A. Prevalence, risk factors and evaluation of a screening strategy for chronic hepatitis C and B virus infections in healthy company employees. Eur J Epidemiol 2002; 17:721-8. [PMID: 12086089 DOI: 10.1023/a:1015671627577] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
A cross-sectional study was carried out in employees of 17 Greek companies with the aim of assessing the prevalence of hepatitis B (HBV) and hepatitis C (HCV) virus, identifying associated prognostic/risk factors and evaluating the effectiveness of a questionnaire as a pre-screening tool. All participants were asked to complete a questionnaire and a random sample of them was asked to provide a blood sample for hepatitis B core antibody (anti-HBc), hepatitis B surface antigen (HBsAg) and antibodies to hepatitis C (anti-HCV) testing. Individual questions or combinations of them were evaluated in terms of their ability to detect HBV or HCV(+) cases. Of 9085 eligible employees, 6074 (67%) completed the questionnaire. Of 990 samples obtained, 19.9% were anti-HBc(+), 2.6% HBsAg(+) and 0.5% anti-HCV(+). All anti-HCV(+) cases had multiple parenteral risk factors. Multiple logistic regression identified associations between anti-HBc and older age, family members with chronic hepatitis, job category and history of transfusion before 1992. HBsAg(+) was associated with older age and history of transfusion before 1992. None of the risk/prognostic factors had sufficient sensitivity and specificity for HBV but report of at least one risk factor identified all HCV(+) cases. Anti-HCV screening of those with at least two parenteral risk factors not only identified all anti-HCV(+) cases but also resulted in 86% decrease in the screening cost. Under the light of recent treatment advances, targeted questionnaire-based screening of asymptomatic people may prove to be a cost-effective way to face hepatitis C.
Collapse
Affiliation(s)
- V Sypsa
- Department of Hygiene and Epidemiology, Athens University Medical School, Greece
| | | | | |
Collapse
|
6
|
Balogun MA, Ramsay ME, Hesketh LM, Andrews N, Osborne KP, Gay NJ, Morgan-Capner P. The prevalence of hepatitis C in England and Wales. J Infect 2002; 45:219-26. [PMID: 12423608 DOI: 10.1053/jinf.2002.1059] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
OBJECTIVES To estimate the background population prevalence of hepatitis C in England and Wales, observe the prevalence over time and assess the extent of infection outside of known risk groups. METHODS Sera from residual specimens from adult patients submitted to laboratories in England and Wales were tested for anti-HCV. Testing was carried out using a cost-effective pooling strategy. RESULTS Although the prevalence of anti-HCV was highest in 1986 (1.07%), in the multivariable analysis, prevalence did not vary significantly between the 3 periods 1986, 1991 and 1996 (P=0.14). The prevalence of infection was higher in males than in females (P=0.0013). An age-period-cohort analysis revealed a cohort effect due to a lower HCV prevalence in the most recent birth cohorts, that is, those born between the calendar years 1971-1975 and 1976-1980. CONCLUSIONS The majority of HCV infections in England and Wales were probably acquired before 1986. Infections in younger males identified in 1996 may signify more recent acquisition by injecting drug use.
Collapse
Affiliation(s)
- M A Balogun
- Immunisation Division, PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London, NW9 5EQ, UK.
| | | | | | | | | | | | | |
Collapse
|
7
|
Bárcena Marugán R, García-Hoz F, Vázquez Romero M, Nash R, Mateos M, González Alonso R, García González M, García Plaza A. Prevention of de novo hepatitis B infection in liver allograft recipients with previous hepatitis B infection or hepatitis B vaccination. Am J Gastroenterol 2002; 97:2398-401. [PMID: 12358263 DOI: 10.1111/j.1572-0241.2002.05994.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
OBJECTIVES To assess de novo hepatitis B virus (HBV) transmission from liver donors with HBV serum markers (HBM) to their recipients and the need for HBV vaccination before liver transplantation. METHODS A total of 108 orthotopic liver transplantations for nonviral disease and the risk of developing de novo hepatitis B based on HBMs before transplantation have been studied. Of the 108 patients, 94 met the study criteria and were divided into two groups: 27 who had HBMs before transplantation (from past infection or by previous vaccination) and 67 who had no HBM. Development of de novo hepatitis B was determined by analytical, serological, and histological parameters. RESULTS No case (0%) of de novo hepatitis B was detected in the pretransplantation HBM group, whereas there were 10 cases (14.5%) in the other group (p < 0.005). CONCLUSIONS The presence of pretransplantation HBM in liver transplant recipients protects these patients against the development of de novo hepatitis B. This is especially important considering that there is a high prevalence of donors with positive hepatitis B core antibody (especially in some countries), and that these donors transmit HBV infection to recipients without HBM in a significant number of cases. Thus, vaccination against HBV in patients who are candidates for liver transplantation is fundamental to avoid cases of de novo hepatitis B.
Collapse
|
8
|
Bárcena Marugán R, García Garzón S, López San Román A, Peña González E, Nasha R, Férnandez Muñoz R, Mateos M, García Plaza A. [Risk of hepatitis B virus transmission from hepatitis B core antibody-positive liver donors]. Med Clin (Barc) 2001; 116:125-8. [PMID: 11222157 DOI: 10.1016/s0025-7753(01)71746-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND To study the hepatitis B virus (HBV) transmission from donors HBsAg-/AntiHBc+ to liver transplant recipients. PATIENTS AND METHOD We studied retrospectively the HBV serological markers in 43 donors from our center and also the serological condition of the 41 recipients. The HBV serological markers were analyzed by ELISA and HBV DNA was detected by hybridation assays. RESULTS 13 donors samples showed some HBV serological markers: 6 anti-HBc and anti- HBs (13.9%), 4 anti-HBc (9%) and 3 anti- HBs (6.9%). There were no cases of hepatitis B among liver recipients from donors with negative serological markers. Among the 13 recipients with HBV serological markers, 9 were followed during 39 (SD 17) months. The 5 recipients with no HBV markers, who received an anti- HBc+ with or without anti- HBs (100%) developed hepatitis B. The two liver recipients with anti-HBs solely, did not developed infection (0%). Of the 41 recipients, 15 had some HBV markers before transplant and two of them received an anti-HBc+ and did not develop the infection (0%). CONCLUSIONS In our study, the prevalence of serological HBV infection in donors and recipients was of 30.2 and 31.7%, respectively. Anti-HBc with or without anti-HBs donors transmitted the HBV infection in all the cases (100%) to the susceptible recipients. The presence of anti-HBs in recipients protected these against the infection. Only the anti-HBs positive donors did not trasmit the HBV infection.
Collapse
|
9
|
Dal-R� R, Garc�a-Corbeira P, Garc�a-de-Lomas J. A large percentage of the Spanish population under 30 years of age is not protected against hepatitis A. J Med Virol 2000. [DOI: 10.1002/(sici)1096-9071(200004)60:4<363::aid-jmv1>3.0.co;2-l] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
10
|
Bart PA, Jacquier P, Zuber PL, Lavanchy D, Frei PC. Seroprevalence of HBV (anti-HBc, HBsAg and anti-HBs) and HDV infections among 9006 women at delivery. LIVER 1996; 16:110-6. [PMID: 8740844 DOI: 10.1111/j.1600-0676.1996.tb00714.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Serum samples from 9006 women, who delivered in Switzerland in 1990 and 1991, were collected around the country. Of these women, 62.7% were Swiss and 37.3% originated from foreign countries. Samples were first screened for anti-HBc and those found positive were further tested for HBsAg, anti-HBs and anti-HDV. Anti-HBc was found in 640 of the 9006 women (overall prevalence, 7.1%; Swiss, 3.3%; foreigners, 13.5%). Of these 640 positive samples, 61 (9.5%) were positive for HBsAg (without anti-HBs), 467 (73.0%) positive for anti-HBs (without HBsAg) and 8 (1.3%) positive for both HBsAg and anti-HBs. The remaining 104 were thus anti-HBc positive without HBsAg or anti-HBs. These 104 specimens with the so-called "isolated anti-HBc" reactivity represented 1.2% of the whole population or 16.3% of the 640 anti-HBc positive mothers. All were HBV DNA negative (PCR). Anti-HDV antibody was found in only five women. HBsAg was seen in 38 of the cord-blood samples from the anti-HBc positive mothers. In this large sampling, we observed a relatively high seroprevalence of HBV infection. Cases with isolated anti-HBc reactivity, being HBV DNA negative by PCR, were probably non-infectious at the time of blood collection.
Collapse
Affiliation(s)
- P A Bart
- Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | | | | | | | | |
Collapse
|
11
|
Arístegui J, Morales JL, Dal-Ré R, González A, Gallego MS, Garrote E. Safety and immunogenicity of an inactivated hepatitis A vaccine in children 2 to 5 years old. Infection 1995; 23:334-8. [PMID: 8557400 DOI: 10.1007/bf01716302] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The reactogenicity and immunogenicity of an inactivated hepatitis A vaccine were assessed. Seventy healthy children aged between 2 and 5 years old, who lacked antibodies against the hepatitis A virus, were enrolled in this study. With a 0-, 1-, and 6-month vaccination schedule, the children received three doses of 360 enzyme-linked immunosorbent assay (ELISA) units of hepatitis A vaccine intramuscularly (deltoid). Safety parameters were recorded in standardized diary cards by the parents on the day of injection and the three following days. Blood tests for liver enzymes and anti-hepatitis A virus antibody analyses were performed the day of screening and 1, 2, 6 and 7 months after the first dose. Anti-hepatitis A virus antibody was tested by ELISA. Titres < 20 mIU/ml were considered negative. For the three hepatitis A vaccine doses administered, 22% (46/210) of the diary cards reported any kinds of signs or symptoms. Soreness at the injection site (9%, 18/210) and malaise (6%, 12/210) were the most common local and systemic reactions reported, respectively. The seroconversion rates were 83, 99 and 100% one month after the 1st, 2nd, and 3rd doses, respectively. The corresponding geometric mean titres were 124, 352, and 2,778 mIU/ml. We conclude that this HAV vaccine is safe and immunogenic in healthy children. As the hepatitis A epidemiology pattern is rapidly changing in our country (and other regions), resulting in an increasing population of susceptible adolescents and young adults, we suggest that the routine vaccination against hepatitis A in pre-school children attending day-care centres should be seriously considered.
Collapse
Affiliation(s)
- J Arístegui
- Dept. of Pediatrics, Basurto Hospital, Spain
| | | | | | | | | | | |
Collapse
|
12
|
Marranconi F, Fabris P, Stecca C, Zampieri L, Bettini MC, Di Fabrizio N, de Lalla F. Prevalence of anti-HCV and risk factors for hepatitis C virus infection in healthy pregnant women. Infection 1994; 22:333-7. [PMID: 7531180 DOI: 10.1007/bf01715541] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The prevalence of anti-HCV antibodies and the risk factors for HCV infection were assessed in 5,672 pregnant women living in North Italy. All reactive sera were confirmed by RIBA-2 test. Anti-HCV positive pregnant women together with an anti-HCV negative control group, were interviewed by standardised questionnaire to identify "known" or "potential" risk factors for HCV infection. The anti-HCV prevalence was 0.7% (40/5,672), higher than that observed among blood donors in the same geographical area (0.2%). The RIBA-2 assay was positive in 60% (24/40) of cases, indeterminate in 10% (4/40) and negative in 30% (12/40). As for "known" risk factors, considering RIBA-2 positivity, intravenous drug use was by far the main risk factor for HCV infection, resulting in a significantly higher risk than in the control group (50% versus 5.9% [O. R. 15.8, CI 5.4-45.5]). The ten RIBA-2 positive women without histories of transfusion or IV drug use had a significantly higher frequency of "sexual contacts with IV drug users" compared to controls (50% vs 4.9% [O. R. 19.0, CI 3.6-94.0]). In conclusion, our study provides evidence that in our geographical area the anti-HCV antibody prevalence is higher in pregnant women than in blood donors and that IV drug use and sexual contacts with IV drug users represent the most important risk factors for HCV infection among young women in North Italy.
Collapse
Affiliation(s)
- F Marranconi
- Dept. of Infectious Diseases, S. Bortolo Hospital, Vicenza, Italy
| | | | | | | | | | | | | |
Collapse
|
13
|
Perez-Trallero E, Cilla G, Urbieta M, Dorronsoro M, Otero F, Marimon JM. Falling incidence and prevalence of hepatitis A in northern Spain. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 1994; 26:133-6. [PMID: 8036467 DOI: 10.3109/00365549409011775] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The prevalence of hepatitis A virus antibodies was studied using a commercial ELISA method. 2,214 subjects were included, 1,211 in 1992 and 1,003 during 1986-87. In 1992 the seroprevalence rates among subjects 1-9, 10-19, 20-29 and 30-39 years old were 2.4%, 21%, 57.6% and 87.5% respectively, as compared with 7.7%, 37.9%, 80.6% and 98.1% respectively, in a similar group of subjects studied 5 years earlier (p < or = 0.001). The reported number viral hepatitis cases declined from 35.0 per 100,000 people in 1984 to 8.9 per 100,000 in 1992. Concurrently, the age when contracting the disease rose. The mean age for patients acquiring hepatitis A was 15.5 in 1986-88 and 20.1 in 1991-92. The decline in incidence and prevalence of HAV infection indicates a progressive and continuous decrease in HAV circulation in this geographical area.
Collapse
Affiliation(s)
- E Perez-Trallero
- Microbiology Service, Hospital NS Aránzazu, San Sebastián, Spain
| | | | | | | | | | | |
Collapse
|
14
|
Camarero C, Martos I, Delgado R, Suarez L, Escobar H, Mateos M. Horizontal transmission of hepatitis C virus in households of infected children. J Pediatr 1993; 123:98-9. [PMID: 8391573 DOI: 10.1016/s0022-3476(05)81549-5] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Anti-hepatitis C antibodies were measured in 80 household contacts of 27 children infected with hepatitis C virus. Antibodies were demonstrated in only one brother of an infected patient. The results suggest that intrafamilial transmission from infected children may occur, but at a low rate.
Collapse
Affiliation(s)
- C Camarero
- Department of Pediatrics, Hospital Ramon y Cajal, University of Alcala de Henares, Madrid, Spain
| | | | | | | | | | | |
Collapse
|